Key Takeaways
- Digital-native health platforms captured $28 billion in life sciences revenue between 2023 and 2025, equivalent to 7% of global prescription drug revenue growth over the same period.
- A McKinsey survey of 340 pharma executives conducted in Q1 2026 found that 61% rated digital health competition as a "top-three strategic threat," up from 29% in 2023.
- Legacy pharma groups that made dedicated digital health acquisitions before 2024 are outperforming peers on patient-retention metrics by an average of 18 percentage points.
- Three major European pharma groups have announced digital therapeutics units with combined funding of $4.1 billion since January 2025, signalling a structural rather than opportunistic shift.
Three years ago, the standard response from a legacy pharma executive asked about digital health competition was polite dismissal. That position is no longer tenable. A cohort of digital-native health platforms, spanning direct-to-consumer prescription services, AI-powered chronic disease management apps, and vertically integrated telehealth providers, has collectively absorbed $28 billion in revenue that would previously have flowed to traditional pharmaceutical and healthcare service channels. According to a Q1 2026 survey of 340 pharma executives conducted by McKinsey, 61% now rank digital health disruption as a top-three strategic threat. In 2023, that figure was 29%.
The Platforms That Got There First, and How They Did It
The most aggressive digital health platforms did not compete on drug discovery. They competed on distribution, convenience, and data. Direct-to-consumer prescription platforms grew their combined user base by 214% between 2022 and 2025, primarily by collapsing the distance between diagnosis and dispensing. One telehealth-first chronic care platform serving the US and UK markets reported $1.9 billion in annualised revenue in Q4 2025, with 73% of that revenue generated from branded pharmaceutical products sold at margins legacy pharmacy benefit managers would recognise as competitive.
The structural advantage these platforms hold is the patient relationship. By owning the digital front door, including the initial consultation, the prescription, the fulfilment, and the ongoing adherence data, they have built longitudinal patient profiles that no traditional pharma company possesses at comparable scale. That data advantage compounds over time, feeding AI-driven personalisation that improves retention. Platforms with more than three years of continuous patient data report average retention rates of 67%, against an industry average for branded drug programmes closer to 41%.
Where Legacy Pharma Is Actually Gaining Ground
The narrative of legacy pharma as a passive bystander is increasingly inaccurate. A subset of large-cap groups have moved with genuine speed. Three major European pharma organisations announced dedicated digital therapeutics units between January 2025 and March 2026, with combined committed funding of $4.1 billion. Crucially, two of those units are structured as standalone ventures rather than internal innovation programmes, a deliberate choice to avoid the bureaucratic drag that killed earlier digital health initiatives at the same organisations. An independent analysis of deal activity found that pharma groups completing at least one digital health acquisition before the end of 2024 are outperforming digital-passive peers on patient-retention metrics by an average of 18 percentage points.
"We spent five years treating digital health as a communications problem. The moment we accepted it was a distribution problem, the strategic response became obvious. We were just very late to accept it."
Chief Commercial Officer at a top-10 global pharma group (McKinsey survey respondent, 2026)
The Laggards, and the Cost of Waiting Longer
Not every large pharma group is mounting a credible response. A segment of mid-cap organisations, typically those with revenue between $8 billion and $20 billion annually, has remained largely reactive, citing regulatory uncertainty around prescription digital therapeutics and unresolved questions about reimbursement pathways. That hesitation is carrying a measurable cost. Analysis of US commercial insurance claims data from 2023 to 2025 shows that in five major therapeutic areas, including obesity management, mental health, and type 2 diabetes, digital-native platforms increased their share of first-line patient interactions by an average of 22 percentage points. For pharma groups without a competing digital channel, that shift represents direct revenue exposure of an estimated $6.3 billion annually.
The three strategic postures currently visible across the industry:
- Acquirers: Large-cap groups spending aggressively to buy established platforms with existing patient bases, accepting near-term dilution in exchange for data assets and distribution infrastructure.
- Builders: Mid-to-large groups standing up proprietary digital health ventures, typically focused on companion diagnostics or adherence tools tied to their existing drug portfolios.
- Waiters: Organisations deferring material investment until reimbursement frameworks are clearer, accepting continued share erosion in exchange for reduced execution risk.
The deeper strategic question is not whether legacy pharma can compete with digital-native platforms on technology. Most large groups have both the capital and the scientific capability to close that gap within three to five years. The harder problem is cultural and structural: pharmaceutical organisations are built around decade-long development cycles and regulatory submission processes, not the quarterly product iterations and rapid A/B testing that digital health platforms treat as standard operating procedure. The groups that resolve that tension, whether through acquisition, structural separation, or genuine internal transformation, are the ones best positioned to reclaim the patient relationships that digital health has spent three years building.
